LILRB3 antibody agonism inhibited AML cell death in in vitro, while in vivo AML LILRB3 expression led to increased AML engraftment and mortality in immunodeficient and immunocompetent AML mouse models [53]. Here, LILRB3 is linked to acute myeloid leukemia.